InvestorsHub Logo
Followers 17
Posts 1103
Boards Moderated 0
Alias Born 04/07/2020

Re: kgromax post# 142740

Monday, 01/25/2021 3:17:37 PM

Monday, January 25, 2021 3:17:37 PM

Post# of 233633
CD12 cannot be compared to general statistics. Patients that make a decision to participate in a clinical trial are typically in worse shape than patients that are responding to SOC treatment. So it's safe to say patients in CD12 are the sickest of the sick. That's why it's a trial, to compare Leronlimab to placebo patients not general statistics from patients that are not participating in the trial. No data from the trial has been released so this is only your personal opinion. Your analysis is wrong. Not only wrong you are in a completely different ball park. CD12 will be approved.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News